Back to search results

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Breast Cancer · Triple Negative Breast Cancer · Estrogen-receptor-low Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Emory University, Atlanta, Georgia, United States

    Contact: Study coordinator (Carlos Aguilera, BA) · winshipcto@emory.edu · 404-778-1868
    Contact: Principal Investigator (Shipra Gandhi, MD)

  • IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States

    Contact: Study coordinator (Xin Bryan, RN) · zhongx@iupui.edu · 317-274-5495

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

    Contact: Study coordinator (Xin Bryan, RN) · zhongx@iupui.edu · 317-274-5495
    Contact: Principal Investigator (Kathy Miller, MD)

  • Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States

    Contact: Study coordinator (Xin Bryan, RN) · zhongx@iupui.edu · 317-274-5495

  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

    Contact: Study coordinator (Lindsay Moshides, MS) · Lindsay.Moshides@RoswellPark.org · 716-854-1300
    Contact: Principal Investigator (Sheheryar Kabraji, MD)

  • Duke University, Durham, North Carolina, United States

    Contact: Study coordinator (Samantha Womack, BA) · sam.womack@duke.edu · 919-660-1278
    Contact: Principal Investigator (Alexandra Thomas, MD)
Study leads

  • Kathy Miller, MD

    Principal Investigator

    Indiana University

View source on ClinicalTrials.gov(opens in a new tab)